14 Hrs
Source:
المشهد العربي
Source: المشهد العربي
14 Hrsالمشهد العربي
Source: المشهد العربي
14 HrsReady to play
Ready to play
AstraZeneca has laid off about 600 employees from its U.S. commercial teams focused on respiratory and immune diseases, as part of a shift in resources toward developing innovative treatments and medicines. The move is part of a three-year cost-cutting plan targeting annual pre-tax savings of $1.5 billion, against restructuring costs of up to $2 billion. Those affected included employees who promote the asthma drugs Breztri and Airsupra.
Notice: This Is an AI-Generated Summary
Comments (0)